OverviewChartNewsTraderScreen

DZ Bank Knock-Out REGN/  DE000DJ5X5E8  /

Frankfurt Zert./DZB
2024-06-27  12:34:40 PM Chg.+0.030 Bid2024-06-27 Ask2024-06-27 Underlying Strike price Expiration date Option type
4.210EUR +0.72% 4.210
Bid Size: 5,000		 4.240
Ask Size: 5,000		 Regeneron Pharmaceut... 622.6506 USD 2078-12-31 Call
GlobeNewswire 06-26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 06-26 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 06-22 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 06-18 Kriya Appoints Katherine Eade as Chief Legal Officer
GlobeNewswire 06-18 Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire 06-16 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire 06-13 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 06-11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 06-05 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 06-04 Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 06-03 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 05-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 05-23 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 05-22 Invivyd Elects Two New Independent Members to its Board of Directors
GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire 05-20 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 05-20 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire 05-17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...